BIOMAT Database Logo BIOMAT Database Logo

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant. 2023

William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

To characterize a blaCMY variant associated with ceftazidime/avibactam resistance from a serially collected Escherichia coli isolate. A patient with an intra-abdominal infection due to recurrent E. coli was treated with ceftazidime/avibactam. On Day 48 of ceftazidime/avibactam therapy, E. coli with a ceftazidime/avibactam MIC of >256 mg/L was identified from abdominal drainage. Illumina and Oxford Nanopore Technologies WGS was performed on serial isolates to identify potential resistance mechanisms. Site-directed mutants of CMY β-lactamase were constructed to identify amino acid residues responsible for ceftazidime/avibactam resistance. WGS revealed that all three isolates were E. coli ST410. The ceftazidime/avibactam-resistant strain uniquely acquired a novel CMY β-lactamase gene, herein called blaCMY-185, harboured on an IncI-γ/K1 conjugative plasmid. The CMY-185 enzyme possessed four amino acid substitutions relative to CMY-2, including A114E, Q120K, V211S and N346Y, and conferred high-level ceftazidime/avibactam resistance with an MIC of 32 mg/L. Single CMY-2 mutants did not confer reduced ceftazidime/avibactam susceptibility. However, double and triple mutants containing N346Y previously associated with ceftazidime/avibactam resistance in other AmpC enzymes, conferred ceftazidime/avibactam MICs ranging between 4 and 32 mg/L as well as reduced susceptibility to the newly developed cephalosporin, cefiderocol. Molecular modelling suggested that the N346Y substitution confers the reduction of avibactam inhibition due to steric hindrance between the side chain of Y346 and the sulphate group of avibactam. We identified ceftazidime/avibactam resistance in E. coli associated with a novel CMY variant. Unlike other AmpC enzymes, CMY-185 appears to require an additional substitution on top of N346Y to confer ceftazidime/avibactam resistance.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes

Related Publications

William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.
January 2024, mBio,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichia coli.
February 2023, Microbiology spectrum,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase.
June 2011, Microbial drug resistance (Larchmont, N.Y.),
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
August 2014, Antimicrobial agents and chemotherapy,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China.
January 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
February 2013, Drugs,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
New plasmid-mediated AmpC beta-lactamase (CMY-21) in Escherichia coli isolated in the UK.
July 2006, International journal of antimicrobial agents,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Hijacking a small plasmid to confer high-level resistance to aztreonam-avibactam and ceftazidime-avibactam.
November 2023, International journal of antimicrobial agents,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Plasmid-mediated high-level resistance to erythromycin in Escherichia coli.
March 1986, Antimicrobial agents and chemotherapy,
William C Shropshire, and Bradley T Endres, and Jovan Borjan, and Samuel L Aitken, and William C Bachman, and Christi L McElheny, and Chin-Ting Wu, and Stephanie L Egge, and Ayesha Khan, and William R Miller, and Micah M Bhatti, and Pranoti Saharasbhojane, and Akito Kawai, and Ryan K Shields, and Samuel A Shelburne, and Yohei Doi
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
April 2017, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!